Progress in advancing neurotechnologies is occurring at a time of change in health and social landscapes. As novel brain technologies traverse the realm of preclinical experimentation to real world treatments, questions of readiness, equitable patient access, legal, and intellectual rights surface.

Join us Monday, April 19, at 3:00 pm Eastern to hear leaders of the Pan-Canadian Neurotechnology Ethics Collaboration; Plenary Speaker, Helen Mayberg, MD; and representatives from the Foundation engage in what promises to be an insightful discussion.


Neuroethics for Novel Neurotechnologies

Monday, April 19, 2021
3:00 PM Eastern


Meet the Panelists

Helen Mayberg, MD
Ichan School of Medicine at Mount Sinai

Judy Illes, PhD
University of British Columbia

Nir Lipsman, MD, PhD
Sunnybrook Health Sciences Institute

Patrick McDonald, MD
BC Children's Hospital Research Institute

Matthew Burke, MD
Sunnybrook Research Institute

Jennifer Chandler, LLB, LLM
Centre for Law, Technology and Society

Jessica Foley, PhD
Focused Ultrasound Foundation

Suzanne LeBlang, MD
Focused Ultrasound Foundation

  • Jason Sheehan, MD, PhD, Professor of Neurosurgery at the University of Virginia, has joined the Foundation as the Senior Advisor for Brain Tumor Research.
  • He will help define the Foundation’s strategy for brain tumor research, engage in Foundation-initiated research, and interface with medical societies.

Key Points

  • Liquid biopsy is a blood test used to diagnose and monitor treatment of brain tumors.
  • Nine patients with glioblastoma (GBM) underwent liquid biopsy before and after focused ultrasound treatment that disrupted the blood-brain barrier to enhance chemotherapy delivery.
  • This first-in-human study – recently published in Neuro-Oncology – found focused ultrasound enriched the amount of circulating brain tumor biomarkers in the peripheral blood.
  • The results suggest that focused ultrasound could reduce the need for invasive brain tumor biopsies and allow better monitoring of GBM treatment responses.

Key Points

  • Researchers at West Virginia University have treated the first patient in a first-in-the-world clinical trial investigating focused ultrasound to address opioid use disorder.
  • The trial aims to reduce patients’ substance cravings and addictive behaviors.
  • The COVID-19 pandemic has intensified the addiction crisis, and researchers hope to be able to offer patients a new treatment option.

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Whitelist Instructions